Biogen Inc (BIIB.OQ)
335.16USD
20 Feb 2019
$-0.00 (-0.00%)
$335.16
$332.37
$335.30
$331.90
342,661
524,983
$388.67
$249.24
About
Overall
| Beta: | 0.72 |
| Market Cap(Mil.): | $69,239.67 |
| Shares Outstanding(Mil.): | 211.43 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| BIIB.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 21.50 | 30.48 | 33.70 |
| EPS (TTM): | 15.23 | -- | -- |
| ROI: | 17.59 | 14.95 | 14.45 |
| ROE: | 28.64 | 16.27 | 15.96 |
Biogen beats estimates on multiple sclerosis drugs sales
Biogen Inc beat analysts' estimates for fourth-quarter profit and revenue on Tuesday, buoyed by higher sales of its top-selling multiple sclerosis drugs, and forecast full-year profit ahead of Wall Street expectations.
UPDATE 2-Biogen beats estimates on multiple sclerosis drugs sales
Jan 29 Biogen Inc beat analysts' estimates for fourth-quarter profit and revenue on Tuesday, buoyed by higher sales of its top-selling multiple sclerosis drugs, and forecast full-year profit ahead of Wall Street expectations.
CORRECTED-UPDATE 1-Biogen beats estimates on Spinraza, Tecfidera strength
Jan 29 Biogen Inc beat analysts' estimates for fourth-quarter profit and revenue on Tuesday, driven by demand for its muscle disease treatment Spinraza and top-selling multiple sclerosis drug Tecfidera.
Drugmaker Biogen's fourth-quarter revenue rises 6.6 pct
Jan 29 Biogen Inc reported a 6.6 percent rise in fourth-quarter revenue on Tuesday, driven by higher sales of its blockbuster muscle disease treatment Spinraza.
Ireland demands $1.9 billion in back taxes from Perrigo
DUBLIN Ireland's tax authorities have demanded that drugmaker Perrigo , formerly known as Elan, pay 1.64 billion euros ($1.9 billion) in taxes relating to the calendar year 2013, a U.S. securities filing showed.
Ireland demands $1.9 billion in back taxes from Perrigo
DUBLIN Ireland's tax authorities have demanded that drugmaker Perrigo , formerly known as Elan, pay 1.64 billion euros (1.48 billion pounds) in taxes relating to the calendar year 2013, a U.S. securities filing showed.
Ireland demands $1.9 bln in back taxes from Perrigo
DUBLIN, Dec 21 Ireland's tax authorities have demanded that drugmaker Perrigo, formerly known as Elan, pay 1.64 billion euros ($1.9 billion) in taxes relating to the calendar year 2013, a U.S. securities filing showed.
Swiss stocks - Factors to watch on Dec. 21
ZURICH/BERLIN, Dec 21 The Swiss blue-chip SMI, which is down 10.3 percent on the year, was seen opening 0.1 percent lower at 8,404 points on Friday, according to premarket indications by bank Julius Baer.
U.S. body says gene therapy may be more cost effective for spinal muscular atrophy
NEW YORK/ZURICH Biogen Inc's Spinraza treatment for spinal muscular atrophy and Swiss drugmaker Novartis AG's experimental gene therapy are both expensive, but the gene therapy could be more cost effective once more is known about its U.S. price and long-term success rates, a preliminary report from an independent U.S. nonprofit organization said on Thursday.
UPDATE 1-U.S body says gene therapy may be more cost effective for spinal muscular atrophy
NEW YORK/ZURICH, Dec 20 Biogen Inc's Spinraza treatment for spinal muscular atrophy and Swiss drugmaker Novartis AG's experimental gene therapy are both expensive, but the gene therapy could be more cost effective once more is known about its U.S. price and long-term success rates, a preliminary report from an independent U.S. nonprofit organization said on Thursday.
Estimates